Steering
OtherFine tuning of the STN-DBS settings
NCT Number: NCT04578678
The primary objective of the study is to determine if subthalamic nucleus (STN) deep brain stimulation (DBS) using the Vercise directional leads improves neuropsychiatric state and neuropsychiatric fluctuations 12 months after surgery in a large consecutive series of STN-DBS Parkinson's disease (PD) patients.
Looking for future studies?
Notify MeAll sexes
Observational
Hospices Civils de Lyon (Centre Hospitalier Universitaire de Lyon), Lyon, France
This project of further use of health-related data with consent by the participants is a prospective, international project to evaluate the improvement of neuropsychiatric symptoms and the quality of life 12 months after surgery in a large consecutive series of STN-DBS PD patients using novel implantable Neurostimulator Systems (Boston Scientific). The project will investigate if a fine tuning of the STN-DBS settings could alleviate neuropsychiatric fluctuations, apathy as well as DBS-induced dysarthria and global motor state. The tuning is performed in agreement with the instruction for use of all devices used. Further objectives are validation of new tools that are presently entering clinical routine in optimizing postoperative management like individual current sources, steering, imaging of volume of tissue activated, and beta-oscillations.
The data originates from patients suffering from levodopa-responsive PD which are not adequately controlled by dopaminergic medication and therefore receive STN-DBS as a routine standard of care with routinely collected data.
In total 110 patients who are candidates for STN-DBS will be enrolled in four participating sites in Switzerland and the EU.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For all subjects:
Exclusion criteria
Fine tuning of the STN-DBS settings
Time frame: Follow-up ≤ 5 Weeks
Evaluation of the Neuropsychiatric Fluctuations Scale (NFS) in different states (ON/OFF) to evaluate if non-motor fluctuations are present. The bigger the difference between the two subscores ('ON psychological state' and 'OFF psychological sate') in the different states are, the more non-motor fluctuations are present.
Time frame: Follow-up ≤ 5 Weeks
Motor improvement following STN-DBS using the Vercise directional leads will be assessed by comparing MDS-UPDRS III score (International Parkinson and Movement Disorder Society) during the study in different states (ON/OFF). The minimum and maximum values are: 0-132, where a higher score means a worse outcome.
Time frame: Follow-up ≤ 5 Weeks
Dysarthria will be measured during the study by Voice Handicap Index 30 (VHI) scale. The minimum and maximum values are: 0-120, where a higher score means a worse outcome.
Time frame: Follow-up ≤ 5 Weeks
Apathy will be measured during the study by Dimensional Apathy Scale (DAS). The minimum and maximum values are: 0-72, where a higher score means a worse outcome.
Insel Gruppe AG, University Hospital Bern
Other
Can Subthalamic Stimulation Using Directional Electrodes Improve Postoperative Management in Parkinson's Disease: A Post-market Study - Steeropt
Acronym: Steeropt
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04617496
Articulation Disorders, Basal Ganglia Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT06418152
Basal Ganglia Diseases, Brain Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT01563341
Basal Ganglia Diseases, Brain Diseases
Jacksonville, Florida, United States
View Trial DetailsNCT02935842
Articulation Disorders, Basal Ganglia Diseases
Basel, Canton of Basel-City, Switzerland
View Trial Details